| 胡婕,刘瑞菡,王高翔,等.CC类趋化因子 22、叉头框蛋白 P1在急性髓系白血病外周血中的表达及对预后的预测价值[J].安徽医药,2024,28(2):371-375. |
| CC类趋化因子 22、叉头框蛋白 P1在急性髓系白血病外周血中的表达及对预后的预测价值 |
| Expression levels of CCL22 and FOXP1 in peripheral blood of patients with acute myeloid leukemia and their prognostic predictivevalue |
| |
| DOI：10.3969/j.issn.1009-6469.2024.02.035 |
| 中文关键词: 白血病，髓样，急性 CC类趋化因子 22 叉头框蛋白 P1 预后价值 |
| 英文关键词: Leukemia,myeloid,acute C-C class chemokine 22 Forkhead box P1 Prognostic value |
| 基金项目:孝感市自然科学计划立项项目( XGKJ2022010036) |
|
| 摘要点击次数: 1025 |
| 全文下载次数: 381 |
| 中文摘要: |
| 目的探讨急性髓系白血病( AML)病人外周血中 CC类趋化因子 22(CCL22)、叉头框蛋白 P1(FOXP1)表达水平及其预后预测价值。方法选择 2018年 5月至 2019年 5月在孝感市中心医院、华中科技大学医学院附属同济医院及咸宁市中心医院确诊的 68例 AML病人设为观察组，另取同期健康体检者 68例作为对照组，采用酶联免疫法测定外周血 CCL22，FOXP1表达水平，分析其与临床特征的关系；采用 Pearson法分析 AML病人外周血中 CCL22，FOXP1表达的相关性；采用 Kaplan-Meier生存分析法分析 CCL22，FOXP1表达与总体生存时间( OS)的关系；采用 Cox比例风险回归模型分析病人预后死亡的影响因素。结果与对照组相比，观察组 CCL22［(600.27±62.89)ng/L比( 756.84±100.86)ng/L］，FOXP1［(56.02±13.68)ng/L比( 103.06±22.16) ng/L］表达均明显升高( t=10.86，14.90，均 P<0.05)； CCL22，FOXP1表达水平与 AML病人年龄、性别、染色体预后、血红蛋白(HGB)、血小板计数( PLT)、 FMS样酪氨酸激酶 3-内部串联重复基因( FLT3-ITD)、核仁磷酸蛋白基因 1(NPM1)突变无关( χ2=0.06~2.95，均 P>0.05)与脾肿大、白细胞计数( WBC)有关( χ2=5.90~8.59，均 P<0.05)； Pearson法分析结果显示， AML病人外周血中 CCL22与 FOXP1表，达呈正相关(r=0.27，P<0.05)； Kaplan-Meier法分析结果显示， AML病人外周血 CCL22，FOXP1高表达组 3年生存率均低于低表达组( 47.06%比 70.59%，44.12%比 73.53%)(χ2=6.50，P<0.05)；多因素 logistic回归分析结果显示， CCL22，FOXP1是影响 AML病人预后的独立危险因素( P<0.05)。结论 CCL22，FOXP1在 AML病人外周血中呈高表达， CCL22，FOXP1高表达组病人 3年生存率均低于低表达组，二者有望成为 AML病人预后评估的分子标志物。 |
| 英文摘要: |
| Objective To investigate the expression levels of C-C class chemokine 22 (CCL22) and forkhead box P1 (FOXP1) in pe.ripheral blood of patients with acute myeloid leukemia (AML) and their prognostic value.Methods From May 2018 to May 2019, 68AML patients diagnosed in Xiaogan Central Hospital, Tongji Hospital affiliated to Huazhong University of Science and TechnologySchool of Medicine, and Xianning Central Hospital were gathered as the research group, another 68 healthy people who came to ourhospital for physical examination were gathered as the control group. The expression levels of CCL22 and FOXP1 in peripheral bloodwere determined by enzyme-linked immunosorbent assay, and their relationship with clinical characteristics was analyzed; Pearsonmethod was used to analyze the correlation of CCL22 and FOXP1 expression in peripheral blood of AML patients; Kaplan-Meier surviv. al analysis was used to analyze the relationship between the expression levels of CCL22 and FOXP1 in peripheral blood of AML pa.tients and overall survival time (OS); Cox proportional hazards regression model was used to analyze the influencing factors of prognosisand death of patients. Results Compared with healthy subjects (control group), the expressions of CCL22[(600.27±62.89)ng/L vs. (756.84±100.86) ng/L] and FOXP1[(56.02±13.68)ng/L vs. (103.06±22.16) ng/L] in peripheral blood of AML patients were obviously in. creased (t=10.86,14.90,all P<0.05);the expression levels of CCL22 and FOXP1 were not related to age, gender, chromosomal prognosis,hemoglobin (HGB), and platelet count (PLT) in AML patients (χ2=0.06-2.95, all P>0.05), but were related to splenomegaly and white blood cell count (WBC) (χ2=5.90-8.59, all P<0.05); the results of Pearson analysis showed that the expressions of CCL22 and FOXP1 inperipheral blood of AML patients were positively correlated (r=0.27, P<0.05); the results of Kaplan-Meier analysis showed that the 3-year survival rates of the high expression groups of CCL22 and FOXP1 in peripheral blood of AML patients were lower than those of thelow expression group (47.06% vs. 70.59%, 44.12% vs. 73.53%)(χ2=6.50, P<0.05); multivariate logistic regression analysis showed thatCCL22 and FOXP1 were independent risk factors affecting the prognosis of AML patients (P<0.05).Conclusions CCL22 and FOXP1 are highly expressed in the peripheral blood of AML patients. The 3-year survival rates of CCL22 and FOXP1 high expression groupswere lower than those of low expression groups, and they may become molecular markers for prognostic evaluation of AML patients. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
